NCIt definition : An orally bioavailable heterobifunctional protein degrader of the v-raf murine sarcoma
viral oncogene homolog B1 (BRAF) mutant V600E, with potential antineoplastic activity.
CFT1946 is comprised of a cereblon (CRBN)-binding moiety and a BRAF V600E-binding
moiety. Upon oral administration, BRAF V600E degrader CFT1946 targets and binds to
BRAF V600E with its BRAF V600E-binding moiety. Upon BRAF V600E binding, the CRBN-binding
moiety binds to CRBN, a component of the CRL4-CRBN E3 ubiquitin ligase complex, which
directs proteins for destruction, resulting in the proteasome-mediated degradation
of BRAF V600E. This leads to the inhibition of an over-activated MAPK signaling pathway
downstream in BRAF V600E-expressing tumor cells and a reduction in tumor cell proliferation.
BRAF belongs to the raf/mil family of serine/threonine protein kinases and plays a
role in regulating the MAP kinase/ERKs signaling pathway. The valine to glutamic acid
substitution at residue 600 accounts for the majority of BRAF gene mutations. The
oncogenic product, BRAF V600E, exhibits a markedly elevated activity that over-activates
the MAPK signaling pathway.;